华仁药业(300110.SZ)：2025年中报净利润为3733.29万元、同比较去年同期下降49.01%

Financial Performance - The total revenue for Huarun Pharmaceutical in the first half of 2025 was 624 million yuan, a decrease of 148 million yuan compared to the same period last year, representing a year-on-year decline of 19.13% [1] - The net profit attributable to shareholders was 37.33 million yuan, down 35.88 million yuan from the same period last year, reflecting a year-on-year decrease of 49.01% [1] - The net cash inflow from operating activities was 170 million yuan, an increase of 8.53 million yuan compared to the same period last year, marking a 5.29% year-on-year increase and achieving four consecutive years of growth [1] Profitability and Efficiency Ratios - The latest asset-liability ratio is 58.74%, a decrease of 0.96 percentage points from the previous quarter, but an increase of 15.25 percentage points compared to the same period last year [3] - The latest gross profit margin is 37.73%, an increase of 1.44 percentage points from the previous quarter, achieving two consecutive quarters of growth, but a slight decrease of 0.02 percentage points compared to the same period last year [3] - The latest return on equity (ROE) is 2.79%, an increase of 0.12 percentage points compared to the same period last year [3] - The diluted earnings per share are 0.03 yuan, a decrease of 0.03 yuan compared to the same period last year, reflecting a year-on-year decline of 48.95% [3] - The latest total asset turnover ratio is 0.18 times, an increase of 0.03 times compared to the same period last year, representing a year-on-year increase of 19.72% [3] - The latest inventory turnover ratio is 1.30 times, a decrease of 0.17 times compared to the same period last year, reflecting a year-on-year decline of 11.46% [3] Shareholder Structure - The number of shareholders is 42,000, with the top ten shareholders holding 529 million shares, accounting for 44.77% of the total share capital [3] - The largest shareholder is Xi'an Qujiang Tian Shou Health Investment Partnership, holding 20.00% of the shares [3]